JPRN-UMIN000006742
Completed
Phase 2
Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II study - Efficacy and Safety study of adjuvant therapy with XELOX for the Japanese patient with StageIII curative resection Colon cancer
Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group0 sites195 target enrollmentNovember 20, 2011
ConditionsColon cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Colon cancer
- Sponsor
- Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group
- Enrollment
- 195
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Present with diarrhea 2\) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 3\) CTCAE v4\.0\>Grade1 of peripheral neuropathy 4\) regular use of insulin 5\) uncontrollable congestive heart failure, angina,hypertension, arrhythmia 6\) Severe mental disease 7\) active infection 8\) Pregnant or breast\-feeding women 9\) Woman might be pregnant 10\) Inadequate physical condition, as diagnosed by primary physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Early Phase 1
The Effectiveness of the adjuvant treatment with a compound of sedge plant, saffron and honey to conventional treatment for improvement of cognitive performance of patients with dementiaIRCT2016101030255N1Vice Chancellor for research of Isfahan University of Medical Sciences60
Recruiting
Not Applicable
Clinical efficacy study of neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for resectable pancreatic cancerpancreatic cancerJPRN-UMIN000046456Kyoto Katsura Hospital40
Active, not recruiting
Phase 1
Evaluation of the benefit of using hydroxychloroquine for uncomplicated term pregnancy in patients with primary obstetric antiphospholipid syndromePrimary obstetrical antiphospholipid syndromeMedDRA version: 20.0Level: PTClassification code 10002817Term: Antiphospholipid syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-004866-86-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)110
Completed
Not Applicable
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies.Salivary gland tumorJPRN-UMIN000024669Chiba University Hospital6
Completed
Phase 1
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with high-grade salivary grand tumor followed by standard therpies.High-grade salivary grand tumorJPRN-UMIN000011509Department of Otorynolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University9